Interleukin-1β and tumor necrosis factor (TNF)-α sensitize human thyroid epithelial cells to TNF-related apoptosis-inducing ligand-induced apoptosis through increases in procaspase-7 and bid, and the down-regulation of p44/42 mitogen-activated protein kinase activity

被引:24
作者
Mezosi, E
Wang, SH
Utsugi, S
Bajnok, L
Bretz, JD
Gauger, PG
Thompson, NW
Baker, JR
机构
[1] Univ Michigan, Med Ctr, Ctr Biol Nanotechnol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Med Ctr, Dept Med, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Med Ctr, Dept Physiol, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Med Ctr, Dept Surg, Ann Arbor, MI 48109 USA
关键词
D O I
10.1210/jc.2003-030697
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary thyroid cells are resistant to TNF-related apoptosis-inducing ligand ( TRAIL). Previously we showed that the combination of IL-1beta and TNFalpha facilitated TRAIL-mediated apoptosis in these cells and enhanced cell surface expression of TRAIL receptors. The aim of this study was to further characterize the mechanism by which these cytokines sensitized primary thyroid cells to TRAIL-mediated apoptosis. IL-1beta and TNFalpha increased the concentrations of procaspase-7 and Bid. In contrast, the p44/42 MAPK (Erk) pathway was active in thyroid cells and this activity was significantly decreased after exposure to IL-1beta/TNFalpha. A MAPK kinase inhibitor ( U0126) could enhance the cytokine-induced sensitization of thyroid cells to TRAIL, reinforcing the inhibitory role of Erk on TRAIL signaling. In conclusion, IL-1beta/ TNFalpha treatment sensitizes human thyroid cells to TRAIL-mediated apoptosis through increased surface expression of TRAIL receptors, increased expression of procaspase-7 and Bid, and the inhibition of p44/42 MAPK (Erk) pathway.
引用
收藏
页码:250 / 257
页数:8
相关论文
共 51 条
[1]  
Abe K, 2000, ANN NY ACAD SCI, V926, P52
[2]   Fas (APO-1, CD95)-mediated apoptosis in thyroid cells is regulated by a labile protein inhibitor [J].
Arscott, PL ;
Knapp, J ;
Rymaszewski, M ;
Bartron, JL ;
Bretz, JD ;
Thompson, NW ;
Baker, JR .
ENDOCRINOLOGY, 1997, 138 (11) :5019-5027
[3]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[4]   TRAIL receptor-2 signals apoptosis through FADD and caspase-8 [J].
Bodmer, JL ;
Holler, N ;
Reynard, S ;
Vinciguerra, P ;
Schneider, P ;
Juo, P ;
Blenis, J ;
Tschopp, J .
NATURE CELL BIOLOGY, 2000, 2 (04) :241-243
[5]  
Bonavida B, 1999, INT J ONCOL, V15, P793
[6]   Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells [J].
Bretz, JD ;
Mezosi, E ;
Giordano, TJ ;
Gauger, PG ;
Thompson, NW ;
Baker, JR .
CELL DEATH AND DIFFERENTIATION, 2002, 9 (03) :274-286
[7]   Apoptosis and autoimmune thyroid disease: following a TRAIL to thyroid destruction? [J].
Bretz, JD ;
Baker, JR .
CLINICAL ENDOCRINOLOGY, 2001, 55 (01) :1-11
[8]   TRAIL death pathway expression and induction in thyroid follicular cells [J].
Bretz, JD ;
Rymaszewski, M ;
Arscott, PL ;
Myc, A ;
Ain, KB ;
Thompson, NW ;
Baker, JR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (33) :23627-23632
[9]   Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy [J].
Chinnaiyan, AM ;
Prasad, U ;
Shankar, S ;
Hamstra, DA ;
Shanaiah, M ;
Chenevert, TL ;
Ross, BD ;
Rehemtulla, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) :1754-1759
[10]   CELL-POPULATION KINETICS IN DOG AND HUMAN ADULT THYROID [J].
COCLET, J ;
FOUREAU, F ;
KETELBANT, P ;
GALAND, P ;
DUMONT, JE .
CLINICAL ENDOCRINOLOGY, 1989, 31 (06) :655-665